Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 400 of 866 entries
View as:

A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis

Phase: N/A Priority: Normal
NCT ID: NCT06461897 Org: User:
Start: 08/19/24 End: 07/31/30 Due: 07/31/31

A Study of the Efficacy and Safety of Upadacitinib in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

Phase: N/A Priority: Normal
NCT ID: NCT03345849 Org: User:
Start: 12/07/17 End: 01/13/22 Due: 01/13/23

Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases

Phase: N/A Priority: Normal
NCT ID: NCT03339089 Org: User:
Start: 05/18/18 End: 07/08/21 Due: 07/08/22

A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

Phase: N/A Priority: Normal
NCT ID: NCT02993523 Org: User:
Start: 02/02/17 End: 01/23/26 Due: 01/23/27

Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT05738850 Org: User:
Start: 02/15/23 End: 05/31/24 Due: 05/31/25

Safety Study of ABT-263 in Combination With Paclitaxel in Subjects With Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00891605 Org: User:
Start: 07/31/09 End: 07/31/12 Due: 07/31/13

A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia)

Phase: N/A Priority: Normal
NCT ID: NCT04198415 Org: User:
Start: 02/03/20 End: 10/21/22 Due: 10/21/23

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05445778 Org: User:
Start: 12/27/22 End: 04/30/29 Due: 04/30/30

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

Phase: N/A Priority: Normal
NCT ID: NCT06810505 Org: User:
Start: 02/13/25 End: 03/31/31 Due: 03/31/32

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT06236438 Org: User:
Start: 04/10/24 End: 10/31/31 Due: 10/31/32

Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT05753501 Org: User:
Start: 06/09/23 End: 03/31/31 Due: 03/31/32

A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER)

Phase: N/A Priority: Normal
NCT ID: NCT02799381 Org: User:
Start: 02/09/17 End: 09/19/19 Due: 09/19/20

A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab

Phase: N/A Priority: Normal
NCT ID: NCT03368859 Org: User:
Start: 03/20/18 End: 12/18/19 Due: 12/18/20

A Study to Assess Adverse Events of Intramuscular AGN-151586 Injection in Adult Participants With Glabellar Lines

Phase: N/A Priority: Normal
NCT ID: NCT05248893 Org: User:
Start: 02/25/22 End: 06/26/23 Due: 06/26/24

Open-label Study of Adalimumab in Japanese Subjects With Hidradenitis Suppurativa

Phase: N/A Priority: Normal
NCT ID: NCT02904902 Org: User:
Start: 09/06/16 End: 05/30/19 Due: 05/30/20

A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)

Phase: N/A Priority: Normal
NCT ID: NCT02986373 Org: User:
Start: 12/15/16 End: 07/30/18 Due: 07/30/19

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02709889 Org: User:
Start: 09/23/16 End: 08/27/19 Due: 08/27/20

Real World Evidence of the Effectiveness of Paritaprevir/Ritonavir (r) - Ombitasvir, + Dasabuvir Without Ribavirin in Participants With Chronic Hepatitis C and Compensated Liver Cirrhosis in the Russian Federation

Phase: N/A Priority: Normal
NCT ID: NCT03053180 Org: User:
Start: 03/20/17 End: 12/18/17 Due: 12/18/18

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Capsules of Galicaftor/Navocaftor/ABBV-119 or Galicaftor/Navocaftor/ABBV-576 Combination Therapies in Adult Participants With Cystic Fibrosis

Phase: N/A Priority: Normal
NCT ID: NCT04853368 Org: User:
Start: 09/20/21 End: 06/05/23 Due: 06/05/24

Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated Pain

Phase: N/A Priority: Normal
NCT ID: NCT01760954 Org: User:
Start: 12/28/12 End: 04/15/16 Due: 04/15/17

Study Of Effects Of Oral CREON Capsules In Adult Participants With Exocrine Pancreatic Insufficiency Not Due To Cystic Fibrosis, Chronic Pancreatitis, Pancreatectomy, Or Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04315311 Org: User:
Start: 05/06/20 End: 09/22/21 Due: 09/22/22

Study of the Effectiveness and Clinical Practice Use of Glecaprevir Plus Pibrentasvir in Patients With Chronic Hepatitis C Genotypes 1 to 6

Phase: N/A Priority: Normal
NCT ID: NCT03303599 Org: User:
Start: 11/13/17 End: 01/24/20 Due: 01/24/21

A Study to Investigate the Safety and Efficacy of ABBV-105 Alone or in Combination With Upadacitinib (ABBV-599 Combination) in Participants With Active Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT03682705 Org: User:
Start: 10/08/18 End: 03/26/20 Due: 03/26/21

Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients

Phase: N/A Priority: Normal
NCT ID: NCT03339102 Org: User:
Start: 01/25/18 End: 07/16/20 Due: 07/16/21

Assess the Oral Bioavailability of a New ABT-263 Formulation in Subjects With Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00982566 Org: User:
Start: 10/31/09 End: 12/31/10 Due: 12/31/11